Clinical Trial

The Effect of Hydroxytyrosol Administration on Superoxide Dismutase, Pulsatility Index and Resistance Index of Uterine Artery Doppler and Flow-Mediated Dilatation of Brachial Artery In Mothers With Hypertension In Pregnancy

Study acronym: HYDROXY-2
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the effect of hydroxytyrosol 10 mg/day administered for 4 weeks in pregnant individuals with hypertension. This study will assess whether hydroxytyrosol increases serum superoxide dismutase levels, reduces uterine artery Doppler pulsatility and resistance indices, and improves brachial artery flow-mediated dilation. Participants will be randomly assigned to receive either hydroxytyrosol or a matching placebo. Both products will be visually identical to ensure blinding. Participants will take two capsules daily for 4 weeks and attend two study visits for assessments and follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Status change: Recruiting → Active, Not Recruiting 2026-01-06
Trial Details
NCT Number NCT07298759
Lead Sponsor Dr Cipto Mangunkusumo General Hospital
Conditions Hypertension in Pregnancy
Enrollment 52 participants
Start Date 2025-06-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-07